In 2018, the U.S. Food and Drug Administration (FDA) invited comments on its intention to exempt a list of class II devices from premarket notification requirements, including tests assessing genetic health risks. ASHG responded to this request for comment by outlining its support for regulation that brings scientifically valid, evidence-based tests to market, and expressing... Read More
Computational Geneticist and Genetic Epidemiologist, Columbia University and MyHeritage Chris Nowak, ASHG: Briefly describe your current position. Dr. Erlich: I am the Chief Science Officer of MyHeritage and an Assistant Professor of Computer Science at Columbia University (currently on leave of absence). MyHeritage is a large consumer genetics and genealogy company that operates all over... Read More
Neil Lamb, PhD, is Vice President for Educational Outreach at the HudsonAlpha Institute for Biotechnology. He has been a member of ASHG since 2000, served on its Information & Education Committee from 2003-05, and chaired the I&E Committee from 2007-09. Kate Garber, ASHG:Tell us about your position and how it fits into your institution and... Read More
“Learn from yesterday, work for today, plan for tomorrow, dream for the day after tomorrow…and most of your dreams will come true.” Supriyo De, MD/PhD, is a Staff Scientist at the National Institute on Aging (NIA), part of the National Institutes of Health (NIH). He is a leading bioinformatics expert focusing on the integration of... Read More
In 2017, ASHG and 10 international organizations published a position statement on human germline genome editing in The American Journal of Human Genetics. The statement recommended against genome editing culminating in human pregnancy, supported publicly funded in vitro research into its potential clinical applications, and outlined scientific and societal steps necessary before implementation of such... Read More
ASHG uses cookies to provide you with a secure and custom web experience. Privacy Policy